Aeluma Q4 revenue falls on R&D contracts

By Reuters News


Overview

  • US semiconductor firm's Q4 revenue fell yr/yr, driven by R&D contracts

  • Net loss and adjusted EBITDA loss widened due to investments in hiring and manufacturing

  • Company signed CHIPS LOI for up to $30 mln and expanded Sumitomo partnership


Outlook

  • Company says fiscal 2027 will focus on technology and product development and customer engagement expansion

  • Aeluma is negotiating NRE agreements with prospective customers in the AI datacom industry

  • Company says CHIPS R&D funding, if finalized, could accelerate commercialization timeline


Result Drivers

  • INVESTMENTS IN TEAM AND MANUFACTURING - Co said increased net loss and adjusted EBITDA loss were due to investments in hiring and manufacturing readiness

  • NEW CONTRACTS AND PARTNERSHIPS - Co executed six new contracts totaling $5.3 mln and expanded relationships with Tower Semiconductor and Sumitomo Chemical Advanced Technologies

  • INCREASED MANUFACTURING CAPACITY - Co procured additional MOCVD tools to increase wafer production for non-InP platforms


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

$600,000

$575,000 (2 Analysts)

Q4 Loss Per Share

$0.22


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • Wall Street's median 12-month price target for Aeluma Inc is $30.00, about 128.5% above its September 15 closing price of $13.13


Reuters Recommended Reads

  • Sept 14 - ASML extends chipmaking dominance as customers embrace High NA

  • Sept 16 - Smaller phone and laptop makers dig in for years of memory scarcity

  • Sept 14 - ASML examining ways it can make more than 110 EUV tools in 2028, JPMorgan says


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.